Chiltern appoints Dr Sharon Moore executive VP of global quality and medical affairs
pharmafile | December 10, 2009 | Appointment | Research and Development | appointment, chiltern, research and development
Chiltern has appointed Dr Sharon Moore executive VP, global quality and medical affairs.
Prior to joining Chiltern, Sharon served as a pharmacovigilance physician and practiced medicine, served as an investigator, was a member of an Institutional Review Board and authored several publications.
She joined CTMS, a US CRO, in 1998 and served with Chiltern since its acquisition of CTMS in 2007 as global head of quality assurance and executive director, medical affairs.
Dr Moore commented, “I am very excited about the opportunity to represent our global QA, Medical and Pharmacovigilance functions. We work in a dynamic environment with increasing complexity of clinical trials and growing importance of safety surveillance. Our teams are working to strengthen our services and to prepare for new medical developments.”
Dr Moore, who is based at Chiltern’s Bristol, Tennessee, USA office, is a physician with 15 years of industry experience.
“I am delighted to appoint Dr Moore to lead our global quality and medical functions and to have her join our Group Executive Board,” stated Chiltern’s chief executive Glenn Kerkhof. “This is a key scientific appointment and Dr. Moore brings a wealth of experience which will enhance our operational delivery and consultative approach for our clients.”
Sharon has Masters in Public Health (MPH) and Business Administration (MBA), holds an active medical license, and is a Certified Physician Investigator (CPI) through the Academy of Pharmaceutical Physicians and Investigators (APPI).
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
